Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports

• Published in: Targeted oncology 2015-06, Vol.10 (2), p.229-234
• Main Authors: Egron, Adeline, Olivier-Abbal, Pascale, Gouraud, Aurore, Babai, Samy, Combret, Sandrine, Montastruc, Jean-Louis, Bondon-Guitton, Emmanuelle
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adverse Drug Reaction Reporting Systems; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Biomedicine; Databases, Factual; Drug Dosage Calculations; Drug Interactions; Drug-Related Side Effects and Adverse Reactions - etiology; Drug-Related Side Effects and Adverse Reactions - prevention & control; France; Humans; Medication Errors - prevention & control; Medicine; Medicine & Public Health; Off-Label Use; Oncology; Original Research; Pharmacovigilance; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors
• ISSN: 1776-2596; 1776-260X
• DOI: 10.1007/s11523-014-0328-7

Antineoplastic drugs are one of the pharmacological classes more frequently involved in occurrence of “serious” adverse drug reactions. However, few epidemiological data are available regarding the preventability of adverse drug reactions with ambulatory cancer chemotherapy. We assessed the rate and characteristics of “preventable” or “potentially preventable” “serious” adverse drug reactions induced by oral protein kinase inhibitors (PKIs). We performed a retrospective study with all “serious” adverse drug reactions (ADRs) recorded from 1 January 2008 to 31 December 2009 in the French Pharmacovigilance Database with the eight oral protein kinase inhibitors marketed in France: sorafenib, imatinib, erlotinib, sunitinib, dasatinib, lapatinib, nilotinib and everolimus (Afinitor®) using the French adverse drug reactions preventability scale. This study was carried out on 265 spontaneous notifications. Most of adverse drug reactions were “unpreventable” (63.8 %). Around one third were “unevaluable” due to notifications poorly documented (medical history, dosage, use of drugs as first or second intention, concomitant drugs). One (0.4 %) adverse drug reaction was “preventable” with dasatinib (subdural hematoma) and three (1.1 %) were “potentially preventable” (hepatic adverse drug reactions): two with imatinib and one with sorafenib. For these four cases, we identified some characteristics: incorrect dosages, drug interactions and off-label uses. An appropriate prescription could avoid the occurrence of 1.5 % “serious” adverse drug reactions with oral PKIs. This rate is low and further studies are needed to compare our results by using other preventability instruments and to improve the French ADRs Preventability Scale.